argenx SE (ARGX) PT Raised to $675 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
argenx SE (ARGX) PT Raised to $707 at Jefferies
November 22, 2024 11:07 AM ESTJefferies analyst Akash Tewari raised the price target on argenx SE (NASDAQ: ARGX) to $707.00 (from $689.00) while maintaining a Buy rating.
The analyst comments "Myositis: 1) It was an easy decision for ARGX as they're seeing a clear signal across all 3 myositis subsets including on secondary endpoints like time to response & deep responses - it's also fair to assume that historical IVIG data would be considered as reference point when setting "go" threshold, 2) ARGX just got the data & the team will be looking to see if they can benefit from making any changes... More
